Emerging Antiepileptic Drugs for Severe Pediatric Epilepsies
This article reports the clinical trial data and personal experience in treating the severe epilepsies of childhood with the recently Food and Drug Administration-approved new antiepileptic drugs (vigabatrin, rufinamide, perampanel, and clobazam) and those in clinical trials (cannabidiol, stiripentol, and fenfluramine).
Source: Seminars in Pediatric Neurology - Category: Neurology Authors: Basanagoud Mudigoudar, Sarah Weatherspoon, James W. Wheless Source Type: research
More News: Brain | Children | Clinical Trials | Epilepsy | Food and Drug Administration (FDA) | Inovelon | Neurology | Pediatrics | Rufinamide